-
Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A
2026-04-23
Anlotinib hydrochloride stands out as a multi-target tyrosine kinase inhibitor with superior potency and selectivity for angiogenesis research. Its robust inhibition of VEGFR2, PDGFRβ, and FGFR1, coupled with low cytotoxicity, enables highly reproducible endothelial cell workflows and advanced tumor modeling.
-
iPSC-Derived Airway Models for CF Drug Testing: A Multimodal
2026-04-22
This study introduces a robust multimodal induced pluripotent stem cell (iPSC) platform to evaluate cystic fibrosis (CF) therapies, including rare CFTR variants not addressed by current modulators. By integrating adapted functional assays in iPSC-derived airway cells, the research demonstrates genotype-specific drug responses, paving the way for more inclusive and predictive preclinical approaches.
-
MAPK10 Phosphorylation Drives KRT16 Degradation in NSCLC Met
2026-04-22
This study uncovers a phosphorylation-dependent mechanism by which MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis through the ubiquitination and degradation of keratin 16. The findings offer new insight into the MAPK10/KRT16/RNF213 axis as a prognostic marker and therapeutic target, with implications for precision cancer research.
-
Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast
2026-04-21
This paper establishes that simultaneous inhibition of BRD4 and RAC1 disrupts the c-MYC/G9a/FTH1 axis, suppressing growth, stemness, and tumorigenesis in diverse breast cancer subtypes. The findings highlight epigenetic modulation as a promising strategy for targeting cancer progression and suggest new avenues for research using chemical probes such as G9a inhibitors.
-
DAPI Solution (1 mg/mL): Precision Nuclear Visualization in
2026-04-21
DAPI Solution (1 mg/mL) from APExBIO is a robust tool for high-contrast nuclear visualization, enabling reliable viability assessment and apoptosis detection in fixed or compromised cells. This guide delivers evidence-backed workflows, hands-on protocol parameters, and troubleshooting strategies that bridge innovative research findings with practical assay optimization.
-
Aminopeptidase Inhibitor Phebestin: New Antimalarial Mechani
2026-04-20
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial agent with nanomolar activity against both drug-sensitive and resistant Plasmodium falciparum strains. Its low host cytotoxicity and efficacy in in vivo models highlight aminopeptidase inhibition as a promising therapeutic strategy for malaria.
-
MHY1485: mTOR Activator for Autophagy & Follicle Assays
2026-04-20
MHY1485 stands out as a precise mTOR activator, enabling researchers to dissect autophagy inhibition and follicle development with exceptional assay control. This guide covers experimental protocols, troubleshooting strategies, and the translational impact of MHY1485 in advanced cellular workflows.
-
Puerarin Modulates Gut Microbiota and Adipose Thermogenesis
2026-04-19
This study demonstrates that puerarin improves glucose and lipid metabolism in type 2 diabetes (T2D) mice by restoring gut microbiota balance and enhancing adipose tissue thermogenesis. These findings highlight new mechanistic insights for phytotherapeutic strategies in T2D management and suggest opportunities for translational research targeting microbiota and energy homeostasis.
-
BMS 599626 dihydrochloride: Precision EGFR and ErbB2 Inhibit
2026-04-18
BMS 599626 dihydrochloride stands out as a selective EGFR and ErbB2 inhibitor for advanced cancer and senescence research. This guide details practical workflows, experimental best practices, and troubleshooting strategies, uniquely informed by the latest machine learning-driven drug discovery insights and benchmarked protocols.
-
ER-Targeted EISA Peptides for Selective Cancer Cell Fate Mod
2026-04-17
This study introduces a peptide system engineered for enzyme-instructed self-assembly (EISA) that selectively targets the endoplasmic reticulum (ER) in cancer cells, leveraging ALP overexpression to induce ER stress and promote apoptosis and necroptosis. The findings highlight a significant advance in organelle-targeted cancer therapy, lowering effective concentrations and offering a pathway to overcome drug resistance.
-
Protease Inhibitor Cocktail (100X): Preventing Protein Degra
2026-04-16
The Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) offers robust, broad-spectrum protein degradation prevention during extraction workflows. By inhibiting serine, cysteine, aspartic proteases, and aminopeptidases, this reagent ensures sample integrity for advanced applications such as Western blotting and co-immunoprecipitation.
-
Enhancing Cell-Based Assays with DiscoveryProbe™ FDA-approve
2026-04-15
This article delivers scenario-driven insights into how DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) empowers cell viability, proliferation, and cytotoxicity assay workflows. By addressing practical laboratory challenges and referencing peer-reviewed data, we demonstrate why this FDA-approved bioactive compound library is a cornerstone for reproducible high-throughput screening and translational drug discovery.
-
Veratridine: Voltage-Gated Sodium Channel Opener in Assay De
2026-04-14
Veratridine’s precision as a voltage-gated sodium channel opener unlocks advanced experimental workflows in neuroscience, cardiomyocyte modeling, and cancer research. This article delivers actionable protocols, troubleshooting guides, and data-driven insights, translating mechanistic expertise into reproducible results.
-
Z-YVAD-FMK (SKU A8955): Reliable Caspase-1 Inhibition in Res
2026-04-13
This article addresses key challenges in apoptosis and pyroptosis assays and demonstrates how Z-YVAD-FMK (SKU A8955) provides robust, reproducible caspase-1 inhibition. With scenario-driven insights, it guides researchers on experimental design, data reliability, and vendor selection, supporting best practices for cell death and inflammasome studies.
-
MK-2206 dihydrochloride: Precision Inhibition for Apoptosis
2026-04-12
MK-2206 dihydrochloride empowers researchers to dissect the PI3K/Akt/mTOR pathway with nanomolar accuracy, driving reproducible apoptosis and proliferation studies. This article unpacks advanced workflows, troubleshooting, and the translation of cutting-edge metabolic findings into actionable experimental design.